Guerbet (France) sales up as contrast agent phased out
This article was originally published in Clinica
Executive Summary
Guerbet (France) has decided to drop its Telebrix 38 contrast agent and recall stocks in France and abroad over the next few months. The product withdrawal follows several reports to the Agence du Medicament of product crystallisation. The agency asked for some batches to be removed, but Guerbet has withdrawn the product as "a cautious move", Philippe Barthelet, Guerbet's financial director, told Clinica. He says no instances of clinical problems have been reported.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.